Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?

Abstract

Bullous pemphigoid (BP) is the most frequent autoimmune subepidermal bullous disease. At present, the main treatment options are represented by corticosteroids and immunosuppressant drugs. Steroids often need to be administered in high doses, with subsequent adverse events and safety issues, as BP mainly affects elderly people. As dupilumab, a recombinant fully human IgG4 monoclonal antibody with binding specificity to human interleukin-4 receptor IL-4Rα has become paramount in the treatment of atopic dermatitis, its use in autoimmune bullous diseases has been theorized and it has been used to treat patients with BP. Dupilumab seems to be an effective and safe option to treat recalcitrant BP. Here, we report the results of a literature review on the use of dupilumab in BP, including a total of 30 treated patients in 9 papers.

• Authors: Roberto Russo, Niccolò Capurro, Emanuele Cozzani, Aurora Parodi
• Journal: Journal of clinical medicine (J Clin Med) Vol. 11 Issue 12 (Jun 12 2022) ISSN: 2077-0383 [Print] Switzerland
• PMID: 35743438 (Publication Type: Journal Article, Review)